Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Strengthens Monoclonal Antibody Access With $560 Million Regeneron Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

One of the first candidates targeted for development will be an interleukin-6 receptor, a potential competitor to TNF inhibitors, for RA.

You may also be interested in...



Regeneron Confident In Relationship With Sanofi After Viehbacher’s Departure

Biotech and French partner remain on track to file PCSK9 inhibitor alirocumab this quarter in U.S. and EU; meanwhile, Eylea continues strong sales growth – but launch in second indication, diabetic macular edema, is slow.

Astellas Extends Deal With Regeneron For Antibody Technology Built Around Growing Oncology Portfolio

TOKYO - Astellas has acknowledged that it is a late-comer to the oncology space, but an extension of a non-exclusive license to Regeneron's VelocImmune technology, potentially through 2023, signals the Japanese company's continued effort to become a significant player in the monoclonal antibody space

First Roche, Then Bristol: Who’s Next?

This first article in a series takes an in-depth look at which pharma/biotech partnerships have the right chemistry to morph from collaboration to merger/acquisition.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel